Scientific Impact Paper Reviews Non-Invasive Prenatal Diagnosis for Single-Gene Conditions

A Scientific Impact Paper published in BJOG examines cell-free fetal DNA testing for single-gene conditions, which collectively affect approximately 1 in 100 births. The available plain-language summary describes non-invasive prenatal diagnosis (NIPD), using placental DNA circulating in maternal blood to test for selected genetic conditions. This is an overview rather than a report of a clinical trial; no study sample or test-performance results are provided.

Testing can be performed from 8 weeks of gestation, earlier than invasive prenatal testing. The summary contrasts maternal blood sampling with amniocentesis and chorionic villus sampling, which it describes as carrying a miscarriage risk of around 1 in 200. NIPD is currently available through the UK NHS in limited scenarios, including families with a previously affected baby and pregnancies with ultrasound findings suggestive of specific conditions. When the condition being tested for is already known through family history, the summary states that testing is diagnostic and does not require confirmatory testing.

For clinicians, the paper highlights the distinction between NIPD for selected genetic conditions and non-invasive prenatal screening/testing for common chromosomal differences. Testing must distinguish placental DNA from maternal cell-free DNA. The supplied summary does not establish performance across conditions or support universal single-gene screening; full-text recommendations and supporting evidence were unavailable.